Assessing immune response in psoriasis patients treated with Tildrakizumab

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study examines the immune response of patients with moderate to severe psoriasis before and after treatment with Tildrakizumab, an IL23 blocker. It is a one-arm, open-label study involving ten subjects who will undergo biopsy and blood sample collection for molecular profiling. The goal is to evaluate how Tildrakizumab affects immune cell function in the skin and blood of these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years of age or older
* Patients with moderate-severe psoriasis or \> 5% body surface area affected.

Exclusion Criteria:

* taking systemic immunosuppressives in the last 4 weeks
* pregnancy
* severe immunodeficiency (either from genetic or infectious causes).
* tuberculosis or other active serious infection
* active systemic malignancy.
* breast-feeding
* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Where it's running

• University of California, San Francisco
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Raymond Cho, MD, PhD — University of California, San Francisco
• Study coordinator: Raymond Cho, MD, PhD
• Email: rashes@ucsf.edu
• Phone: 415-575-0524

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HRS-4139 safety and pharmacology in healthy adults

  This early-phase study tests a single dose of HRS-4139 to see if it is safe and how the body handles it in healthy adults aged 18–55.

  Recruiting Phase 1 Fujian Shengdi Pharmaceutical Co., Ltd. · Changsha, Hunan · NCT07802964

• Total Coumarin botanical cream for psoriasis vulgaris

  This trial will try a botanical Total Coumarin cream applied twice daily for 8 weeks to see if it helps adults with mild to moderate psoriasis.

  Recruiting Phase 3 Psoriasis Research Institute of Guangzhou · New York, New York · NCT07426120

• Tildrakizumab for symptoms and quality of life in Canadians with moderate-to-severe plaque psoriasis (Fitzpatrick III+)

  This study will test how tildrakizumab affects symptoms, safety, and quality of life in adults in Canada with moderate-to-severe plaque psoriasis who are starting treatment through the ILUMYA SUPPORT® Program and have Fitzpatrick skin types III or higher.

  Recruiting at 7 sites Chronicle Academy · Burlington, Ontario and 6 other locations · NCT07370766

• Topical diacerein in plaque psoriasis (adult) explores if a cream helps skin improve

  This trial tests whether applying a topical diacerein cream twice daily for 8 weeks helps adults with mild-to-moderate psoriasis vulgaris improve symptoms more than a placebo.

  Recruiting Phase 4 Cairo University · Cairo · NCT07352306

• Vaspin gene changes and blood vaspin levels in people with psoriasis

  This test will see if specific vaspin gene variants are linked to blood vaspin levels in people with psoriasis.

  Recruiting Aswan University · Aswān · NCT07320872

• Optimizing biologic dosing for psoriasis treatment

  This study is testing if a new way of adjusting psoriasis medication based on blood tests can work just as well as the usual method over 18 months.

  Recruiting at 10 sites Phase 4 University Hospital, Ghent · Bruges and 14 other locations · NCT06398106

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.